Amer Zeidan, MBBS, Yale University, New Haven, CT, comments on the efficacy of ziftomenib as a monotherapy in relapsed/refractory (R/R) acute myeloid leukemia (AML) with NPM1 mutations or MLL rearrangement, discussing an ongoing Phase I study (NCT04067336) evaluating ziftomenib in combination with venetoclax or venetoclax/azacitidine or standard induction chemotherapy in R/R AML.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
